Sierra Capital LLC Decreases Position in ARK Genomic Revolution ETF (BATS:ARKG)

Sierra Capital LLC trimmed its stake in ARK Genomic Revolution ETF (BATS:ARKG) by 32.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,636 shares of the company’s stock after selling 6,035 shares during the period. Sierra Capital LLC’s holdings in ARK Genomic Revolution ETF were worth $298,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Rothschild Investment LLC raised its stake in shares of ARK Genomic Revolution ETF by 15.2% in the fourth quarter. Rothschild Investment LLC now owns 15,150 shares of the company’s stock valued at $357,000 after acquiring an additional 2,000 shares during the period. Union Bancaire Privee UBP SA bought a new position in ARK Genomic Revolution ETF during the 4th quarter valued at about $45,000. Atria Wealth Solutions Inc. raised its position in ARK Genomic Revolution ETF by 121.1% in the 4th quarter. Atria Wealth Solutions Inc. now owns 19,792 shares of the company’s stock worth $466,000 after purchasing an additional 10,841 shares during the period. Sanctuary Advisors LLC bought a new stake in ARK Genomic Revolution ETF in the fourth quarter worth about $401,000. Finally, Hemington Wealth Management boosted its position in shares of ARK Genomic Revolution ETF by 44.6% during the fourth quarter. Hemington Wealth Management now owns 1,310 shares of the company’s stock valued at $30,000 after buying an additional 404 shares during the period.

ARK Genomic Revolution ETF Trading Up 12.3 %

Shares of BATS ARKG opened at $26.51 on Tuesday. The business has a fifty day simple moving average of $25.87 and a 200 day simple moving average of $25.40.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.